FOSUN HEALTH Logo

Esophageal Cancer Treatment

catalogue

Esophageal Cancer Treatment

Esophageal Cancer Treatment

Treatment turns on depth more than on length. A tumour confined to the mucosa can be removed through the endoscope; once it reaches the submucosa the lymph channels are involved, and treatment becomes chemoradiotherapy with or without an operation.

Treatment at a glance

The plan follows depth first and spread second, which produces six recognisable situations:

  • High-grade dysplasia or a tumour confined to the mucosa — endoscopic submucosal dissection or mucosal resection. The oesophagus is preserved and there is no chest incision.
  • Tumour in the submucosa, no involved nodes — oesophagectomy, because the lymph channels have been reached and the nodes cannot be assessed endoscopically.
  • Locally advanced disease, operable — chemoradiotherapy before surgery, then oesophagectomy. This is the standard pathway for both squamous carcinoma and adenocarcinoma in most centres.
  • Adenocarcinoma, operable — perioperative chemotherapy is a recognised alternative to chemoradiotherapy, and the choice is made on the basis of the type, the location and the team's assessment.
  • Not operable — because of the tumour or the patient — definitive chemoradiotherapy, which is also the standard approach for tumours of the cervical oesophagus.
  • Distant spread — systemic treatment, with targeted or immune therapy where a marker supports it.

A single point deserves to be repeated here because it is counter-intuitive: this is one of the cancers where giving treatment before an operation is the standard rather than the exception, and where a patient told they need chemoradiotherapy first has not been denied surgery but placed on the route that leads to it.

Removing a lesion through the endoscope

Endoscopic treatment is the option that exists only for early disease, and it is worth understanding which lesions qualify, because the window closes once the tumour deepens:

  • Endoscopic submucosal dissection — the lesion and the layer beneath it are cut away in one piece, which allows the pathologist to measure the depth of invasion precisely and to say whether the removal was complete. It is the preferred technique for early squamous carcinoma.
  • Endoscopic mucosal resection — used for smaller lesions and for Barrett's-related nodules, and simpler, though it may require several pieces.
  • Ablation for Barrett's — radiofrequency ablation removes the abnormal glandular lining without cutting, and is used for flat dysplasia over a long segment.
  • Who is eligible — high-grade dysplasia and tumours confined to the mucosa, without involved nodes, and with no evidence of invasion into lymph or blood vessels on the specimen.
  • What follows — surveillance endoscopy at intervals, because a new lesion can develop elsewhere in a field that has already produced one.

The reason a single-piece specimen matters so much is that it is the specimen itself which decides whether the endoscopic treatment was sufficient. If the pathologist finds invasion into the submucosa, or tumour at the deep margin, the operation that was avoided becomes necessary after all — and knowing that within weeks is quite different from discovering it months later.

Surgery: removing the oesophagus

Oesophagectomy is among the largest operations in gastrointestinal surgery, because the oesophagus passes through three compartments and the reconstruction has to carry food from the neck to the abdomen. The variants differ in where the surgeon works and where the join is made:

  • Ivor Lewis (two-stage) — an abdominal and a right chest phase, with the join made in the upper chest. The commonest approach for tumours of the lower and middle oesophagus.
  • McKeown (three-stage) — neck, chest and abdomen, with the join made in the neck. Preferred for upper and middle thoracic tumours, because it allows the upper margin to be taken high.
  • Minimally invasive oesophagectomy — the same compartments dissected through keyhole ports and a small utility incision, which reduces wound pain and respiratory complications. The lymph node dissection is performed through the same approach.
  • Lymph node dissection — two-field (chest and abdomen) or three-field (adding the neck), decided by the level of the tumour and by the findings. Because the lymphatic drainage of the oesophagus runs lengthwise, nodes well above the tumour may be involved.
  • Reconstruction — usually a gastric tube brought up to replace the resected oesophagus, with the stomach preserving its blood supply.

The two complications that dominate recovery are a leak from the join between the stomach tube and the remaining oesophagus, and respiratory problems, the latter because the chest is opened and the vagus nerves are divided. Both are managed with drainage, nutrition and respiratory physiotherapy, and both are reasons the operation belongs in a high-volume centre.

Neoadjuvant and adjuvant treatment around surgery

For operable tumours that have reached beyond the mucosa, treatment is given around the operation rather than after it alone — and the evidence for giving it before surgery is stronger here than in most cancers.

  • Neoadjuvant chemoradiotherapy — radiotherapy with weekly chemotherapy given before surgery, most commonly carboplatin with paclitaxel. It shrinks the tumour, improves the chance of a complete removal, and treats nodal disease that the operation may not reach.
  • Perioperative chemotherapy — a fluoropyrimidine and platinum combination given before and after surgery, used particularly for adenocarcinoma as an alternative to chemoradiotherapy.
  • Adjuvant treatment after chemoradiotherapy — where residual tumour is found in the resected specimen, a PD-1 inhibitor given after the operation extends the time before recurrence, and is the reason the PD-L1 score is requested at diagnosis.
  • Nutrition and prehabilitation before surgery — because a patient who cannot eat loses the reserve needed for the operation, dietary support and, where necessary, a feeding tube are part of the preparation rather than afterthoughts.

The practical consequence for a patient planning treatment abroad is that the sequence is set before arrival. Chemoradiotherapy runs for several weeks and must be completed before restaging and the operation, so the whole pathway is planned as one programme rather than as separate episodes with travel in between.

Chemoradiotherapy as the definitive treatment

For some patients chemoradiotherapy is not preparation for an operation but the treatment itself, and it achieves long-term control in a meaningful proportion:

  • Where surgery is not suitable — because of the patient's general condition, lung function or other illness, or because the tumour has reached a structure that cannot be removed.
  • Cervical oesophagus — a tumour at the very top of the oesophagus is treated with chemoradiotherapy as the standard, because the operation that would be required there carries risks that are difficult to justify.
  • The regimen — several weeks of daily radiotherapy with concurrent chemotherapy, most commonly carboplatin with paclitaxel or a fluoropyrimidine with a platinum drug, planned to spare the lungs, heart and spinal cord.
  • Afterwards — restaging to assess the response, with surgery considered in selected patients where the tumour has responded but not disappeared.
  • Salvage surgery — an operation performed for persistent or recurrent disease after chemoradiotherapy, which is feasible but technically harder, and is why the decision between the two pathways is made by a team rather than by a single specialty.

The trade-off worth understanding is that chemoradiotherapy avoids a major operation and its risks, at the cost of a course of treatment lasting several weeks and of a chance that surgery will still be needed later. Which side of that trade-off is preferable depends on the individual, and it is exactly the kind of decision that a multidisciplinary meeting exists to make.

Systemic treatment for advanced disease

When the disease has spread, the aim changes to controlling it, with the choice of regimen driven by the histological type and the molecular markers rather than by the stage number:

  • Fluoropyrimidine and platinum chemotherapy — the backbone of first-line treatment for both types, with a further drug added according to the markers.
  • Trastuzumab — added to first-line chemotherapy where the adenocarcinoma over-expresses HER2. It has no role in squamous carcinoma, which is one reason the type must be known.
  • PD-1 inhibitors — used in advanced disease where PD-L1 expression is high, and for tumours that are mismatch repair deficient, where the response can be substantial and durable.
  • Second-line treatment — chosen on the basis of what was used first, how long the response lasted, and the markers; there is no single standard, and the patient's condition at the time of progression matters as much as the drugs available.
  • Radiotherapy — used to control the primary tumour when swallowing is threatened or bleeding occurs, and for painful deposits elsewhere.

Treatment is given in cycles with restaging at defined intervals, and reassessed rather than simply continued. The reason this matters more in oesophageal cancer than in some others is nutrition: a patient whose swallowing is deteriorating will struggle to tolerate further cycles, so relieving the obstruction early is part of making systemic treatment possible.

Keeping swallowing possible

In this cancer, supportive treatment is unusually central. The ability to eat determines whether a patient can tolerate treatment at all, so relieving obstruction is part of the treatment rather than something done when it fails:

  • Oesophageal stent — a self-expanding metal stent placed through the endoscope restores swallowing within a day or two. It is used where the tumour cannot be removed, and sometimes before chemoradiotherapy so that nutrition can be maintained.
  • Feeding tube or jejunostomy — where a stent is not suitable, or where nutrition must be reliable over a long course of treatment. A feeding tube does not prevent the patient from eating what they can.
  • Nutritional support and dietetic input — texture-modified diets, high-energy supplements, and monitoring of weight and lean mass throughout treatment.
  • Palliative radiotherapy — to slow the tumour, stop bleeding, or relieve pain, including pain from deposits in bone.
  • Pain control and airway management — including treatment of a fistula between the oesophagus and the airway, which is a specific complication of this cancer.

The single most useful thing supportive care provides is continuity of intake. Weight is monitored deliberately rather than incidentally, and a fall in intake is treated as a clinical finding — because the treatment that follows depends on the patient being well enough to receive it.

How the decision is actually made

Oesophageal cancer is planned by a multidisciplinary team — upper gastrointestinal surgery, medical oncology, radiation oncology, gastroenterology, radiology, pathology and dietetics — and this is one of the cancers where the sequence itself, not just the choice of treatment, is decided in that meeting.

  • Depth is agreed jointly — the gastroenterologist, the radiologist and the surgeon review the endoscopic ultrasound and the imaging together, which is how a lesion is assigned to endoscopic treatment, to surgery, or to chemoradiotherapy.
  • The type drives the regimen — squamous carcinoma and adenocarcinoma take different chemotherapy, different radiotherapy fields and, in some cases, different operations.
  • The sequence is fixed before treatment starts — chemoradiotherapy first, chemotherapy around surgery, or definitive chemoradiotherapy, with a defined point at which the plan will be reviewed.
  • Nutrition is decided in the same meeting — whether a stent or a feeding tube is needed, and when, so that it is not arranged in the middle of a course of treatment as an emergency.
  • The plan is written down — patients receive the agreed assessment including the reasoning, which makes a second opinion a comparison of plans rather than of impressions.

Send complete records — the endoscopy and endoscopic ultrasound reports, the biopsy with its markers, and the imaging on disc — and the written assessment is returned within 48 hours of the file being complete, including whether the lesion can be treated endoscopically and what would need to change for the answer to change.

Frequently Asked Questions

Can the whole oesophagus be removed and still allow eating?

Yes. When part or all of the oesophagus is removed, it is replaced by a tube fashioned from the stomach, brought up through the chest and joined to the remaining oesophagus or to the neck. Most patients can eat by mouth afterwards, though portions are smaller, meals take longer and some foods are difficult. Swallowing is reconstructed, not lost — but it is different, and patients who expect it to feel exactly as before are the ones most disappointed.

Is surgery always needed?

No. A tumour confined to the mucosa can be removed through the endoscope and needs no operation at all. Where the oesophagus has been treated with definitive chemoradiotherapy, surgery may never be necessary — particularly for tumours of the cervical oesophagus or for patients whose general condition makes an operation unsafe. What decides it is depth, spread and the patient's fitness, which is why all three are assessed before a plan is made.

What is the difference between neoadjuvant treatment and definitive chemoradiotherapy?

They can use similar drugs and similar radiotherapy, but the intention is different. Neoadjuvant chemoradiotherapy is given before an operation to shrink the tumour and improve the chance of a complete removal, and surgery follows it. Definitive chemoradiotherapy is the treatment itself, given at a somewhat higher dose over a longer course, with no operation planned afterwards. Whether a patient is on one pathway or the other is a decision made by the multidisciplinary team, and it can change if the response to treatment changes.

Deciding between endoscopic treatment, surgery and chemoradiotherapy?

Send the endoscopy report, the biopsy with its HER2 and PD-L1 results, the endoscopic ultrasound report and the CT on disc. Our upper gastrointestinal multidisciplinary team will settle the depth and the treatment route, and return a written assessment within 48 hours of the file being complete.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*